Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.56 |
| ▸ | GLS | O94925 | 2/20 | 0.53 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.51 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CETP | P11597 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | YAP1 | P46937 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1444654 | 0.93 | STS (0.52) | STSGLSTGFBR1CXCR3MAPT | |
| SCHEMBL6863428 | 0.88 | TACR1 (0.48) | STSGLSTGFBR1CXCR3MAPT | |
| SCHEMBL4272965 | 0.86 | HSD17B10 (0.52) | STSGLSCXCR3EPHX2 | |
| SCHEMBL4272968 | 0.86 | HSD17B10 (0.52) | STSGLSCXCR3EPHX2 | |
| SCHEMBL4276665 | 0.86 | HSD17B10 (0.52) | STSGLSCXCR3EPHX2 | |
| SCHEMBL1443815 | 0.86 | KDM4E (0.54) | STSTGFBR1CXCR3MAPTPTPN2 | |
| SCHEMBL4274713 | 0.85 | HSD17B10 (0.48) | STSGLSCXCR3EPHX2 | |
| SCHEMBL4276575 | 0.84 | CYP1A2 (0.43) | STSGLSTGFBR1CXCR3CETP | |
| SCHEMBL4276573 | 0.84 | CYP1A2 (0.43) | STSGLSTGFBR1CXCR3CETP | |
| SCHEMBL4278127 | 0.84 | CXCR3 (0.56) | CXCR3MAPTTACR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| WO-2011032291-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | ZALICUS PHARMACEUTICALS LTD . (CA) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220564-A1 | SELECTIVE CALCIUM CHANNEL MODULATORS | CACNA1G, CACNA1I, CACNA1H | STS 4843/4885GLS 854/4885TGFBR1 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.